Business Context and Reporting Period
Company: Bristol-Myers Squibb Company (BMS)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and nine months ended September 30, 2025
Business Overview: BMS operates as a single segment focused on the discovery, development, and commercialization of innovative medicines for serious diseases, primarily in oncology, hematology, immunology, cardiovascular, and neuroscience.
Key Financial Metrics
| Metric (in millions) | Q3 2025 | Q3 2024 | 9M 2025 | 9M 2024 |
|---|---|---|---|---|
| Total Revenues | $12,222 | $11,892 | $35,692 | $35,958 |
| Net Earnings Attributable to BMS | $2,201 | $1,211 | $5,967 | $(9,020) |
| Diluted EPS (GAAP) | $1.08 | $0.60 | $2.93 | $(4.45) |
| Operating Cash Flow (9M) | $12,182 (2025) vs $10,751 (2024) | |||
| Cash & Equivalents (Balance Sheet) | $15,726 (Sep 30, 2025) vs $10,346 (Dec 31, 2024) | |||
| Total Debt (Short + Long Term) | $48,978 (Sep 30, 2025) vs $49,649 (Dec 31, 2024) | |||
| Effective Tax Rate | 29.5% | 27.5% | 24.0% | (5.3)% |
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 3% in Q3 2025 and decreased 1% year-to-date (YTD) compared to 2024. Growth was driven by the Growth Portfolio (up 18% in Q3) and Eliquis (up 25% in Q3), offset by significant declines in the Legacy Portfolio due to generic erosion (Revlimid down 59%, Sprycel down 59%, Abraxane down 71%).
- Profitability Surge: Net earnings attributable to BMS increased significantly to $2.2 billion in Q3 2025 from $1.2 billion in Q3 2024. YTD earnings turned from a loss of $9.0 billion in 2024 to a profit of $6.0 billion in 2025.
- Expense Reductions: Amortization of acquired intangible assets dropped 65% YTD ($2.5 billion in 2025 vs. $7.2 billion in 2024), primarily due to the full amortization of Revlimid rights in late 2024. Selling, general, and administrative (SG&A) expenses decreased 19% YTD due to strategic productivity initiatives.
- Acquired IPRD Charges: Acquired In-Process Research and Development (IPRD) charges were $633 million in Q3 2025, up from $262 million in Q3 2024, driven by upfront payments for BioNTech ($1.5 billion), Philochem ($350 million), and SystImmune ($250 million) collaborations.
- Balance Sheet: Cash and cash equivalents increased by $5.4 billion to $15.7 billion. Net debt position improved by $6.4 billion to $32.1 billion.
Guidance, Outlook, Risks, and Unusual Items
- Strategic Initiatives: BMS expects to realize annual cost savings of approximately $2.0 billion by the end of 2027 through its ongoing strategic productivity initiative.
- Regulatory & Pricing Risks:
- IRA Impact: The Inflation Reduction Act (IRA) continues to impact pricing. The HHS selected Pomalyst for price negotiation starting in 2027 and set a "maximum fair price" for Eliquis effective January 2026.
- Executive Order: A May 2025 executive order regarding "Most-Favored Nation" pricing creates uncertainty for U.S. product pricing and reimbursement.
- OBBBA: The "One Big Beautiful Bill Act" (OBBBA) enacted in July 2025 allows immediate 100% deduction of qualifying domestic R&D expenses, impacting tax provisions.
- Legal Proceedings:
- Patent Litigation: Ongoing challenges to Eliquis patents in Europe and Pomalyst/Zeposia in the U.S. Generic entry is occurring in various jurisdictions.
- Securities Litigation: A settlement in principle was reached for the Celgene Securities Class Action in September 2025. CVR litigation regarding the Celgene acquisition remains active with jurisdictional disputes.
- Government Litigation: BMS lost appeals regarding the constitutionality of the IRA drug-pricing program and the 340B cash rebate model.
- Unusual Items:
- Restructuring: Total charges for the 2023 Restructuring Plan are expected to reach $2.5 billion through 2027; $1.6 billion has been incurred to date.
- Acquisitions: BMS entered a definitive agreement in October 2025 to acquire Orbital Therapeutics for $1.5 billion (expected to close Q4 2025).
Investor Verification Checklist
- Generic Erosion Trajectory: Verify the timeline and volume impact of generic entry for Revlimid (volume-limited licenses ending Jan 2026), Pomalyst (expected U.S. entry March 2026), and Eliquis (European patent challenges).
- Acquisition Integration: Assess the financial impact and integration progress of recent acquisitions (Karuna, RayzeBio, Mirati, 2seventy bio) and the pending Orbital Therapeutics deal.
- Regulatory Pricing Exposure: Quantify the potential revenue impact of the IRA "maximum fair price" for Eliquis (effective 2026) and the "Most-Favored Nation" executive order.
- IPRD Amortization: Monitor future amortization schedules for newly acquired assets (BioNTech, Philochem, SystImmune) which will increase future expenses.
- Legal Reserves: Review the status of the Celgene CVR litigation and the potential for additional tax reserves related to transfer pricing matters ($160 million added in Q3 2025).